Filter by: patients
Home > Community Treatment Reports and Side Effects > Lotemax Treatment Report
What is Lotemax?

Lotemax® is brand name for loteprednol, an ophthalmic corticosteroid, used for inflammatory conditions of the eye that are steroid responsive and for the treatment of postoperative inflammation following ocular surgery.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Other 2 1 Efficacy_cant_tell
Dry eyes 2 1 Efficacy_major
Inflammation 1 0
Iritis 1 0
Scleritis 1 0
Sjogrens syndrome 1 0

See all 5 patients currently taking Lotemax

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 2

Reported Dosages

  0.5 g daily 1.5 g daily 2 g daily
  3 Number of Patients: 3 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Lotemax (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 2   Course of treatment ended: 67%
Expense 1   Expense: 33%

See all 3 patients who’ve stopped taking Lotemax

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Lotemax

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Taking Lotemax

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Lotemax

Always
 1 50%
Usually
 1 50%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Lotemax

Very
 0 0%
Somewhat
 1 50%
A little
 0 0%
Not at all
 1 50%

Cost

Paid out of pocket

Cost of Lotemax

$200+
 0 0%
$100-199
 0 0%
$50-99
 1 50%
$25-49
 0 0%
< $25
 1 50%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 28, 2012.